News | Stents Peripheral | July 17, 2015

First Subject Enrolled in Veryan Medical's MIMICS-2 study

Joint U.S./European study will assess safety, effectiveness of BioMimics 3D nitinol stent in treatment of femoropopliteal artery

Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD

July 17, 2015 - Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany by the European principal investigator, Prof. Thomas Zeller.

The BioMimics 3D femoropopliteal stent is a self-expanding, nitinol stent with unique three-dimensional helical geometry designed to address the link between blood flow mechanics and vascular disease. The stent's helical curvature imparts a natural curvature to the diseased artery, promoting secondary (swirling) flow and elevated wall shear stress, which has a protective effect on the endothelium.

The helical geometry of BioMimics 3D is also designed to enable coil-spring shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression, causing localized strains that in a straight stent may lead to stent fracture and chronic vascular injury. 

MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the BioMimics 3D Stent System - being conducted under an investigational device exemption (IDE) approved by the U.S. Food and Drug Administration (FDA) - which will enroll 280 subjects in up to 40 sites in the United States and Germany. The U.S. principal investigator is Timothy Sullivan, M.D., chairman of vascular/endovascular surgery at Minneapolis Heart Institute at Abbott Northwestern Hospital.

The purpose of MIMICS-2 is to provide data to support a U.S. premarket approval application (PMA). It will evaluate BioMimics 3D against the performance goals defined by VIVA Physicians Inc. for the safety and effectiveness of nitinol stents used in the treatment of symptomatic disease of the femoropopliteal artery.

Professor Zeller, who was also the PI of the company's Mimics randomized controlled study commented: "The Mimics study data suggested the existence of a patency protective effect provided by the biomimetic characteristics of the BioMimics 3D stent. I am delighted that we have enrolled the first subject today in MIMICS-2 so that BioMimics 3D can be studied in a larger patient cohort."

In the Mimics Study, the Kaplan Meier (KM) survival estimate of freedom from loss of primary patency at two years was 72 percent for BioMimics 3D subjects vs. 55 percent for the control arm. The difference in survival estimate between the two groups by log rank test was significant (P<0.05). Importantly, there was no increase in the KM estimate of clinically driven target lesion revascularization (CDTLR) rate in the BioMimics arm between 12 and 24 months (9 percent at both time-points) compared to a three-fold increase (8 percent at 12 months and 24 percent at 24 months) in the straight stent control arm.

For more information: www.veryanmed.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init